Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis

35Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

We have previously reported that a subset of breast tumors are infiltrated with IL-17A-producing tumor-associated lymphocytes and that IL-17A cytokine is principally associated with estrogen receptor negative (ER-) and triple negative, basal-like tumors. We established that IL-17A producing lymphocytes induced cancer cell proliferation, chemoresistance, and invasion, indicating that IL-17A is a potential therapeutic target for breast malignancies. © 2014 Landes Bioscience.

Cite

CITATION STYLE

APA

Bastid, J., Bonnefoy, N., Eliaou, J. F., & Bensussan, A. (2014). Lymphocyte-derived interleukin-17A adds another brick in the wall of inflammation-induced breast carcinogenesis. OncoImmunology. Landes Bioscience. https://doi.org/10.4161/onci.28273

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free